INGENIUM Emilia Romagna
VC Fund
INGENIUM Emilia Romagna is a VC fund focused on Medical and Biotechnology. INGENIUM Emilia Romagna was started with EUR 5.30 million by the Emilia Romagna region and EUR 1.7 million from fund managers. Managed by META Investment, the nine-year fund operated through the temporary acquisition of minority stakes in high-opportunity technological companies. It is now fully invested.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries INGENIUM Emilia Romagna invests in
Stages INGENIUM Emilia Romagna invests in
Countries INGENIUM Emilia Romagna invests in
Round sizes
Round size
- Seed
- $2.1M–$2.2M
Investment Focus
Industry
- Medical 3 (50%)
- Biotechnology 3 (50%)
- Health Care 2 (33%)
- Privacy 1 (17%)
- Security 1 (17%)
Stage
- Seed 2 (33%)
- Angel 1 (17%)
- Series A 1 (17%)
- Funding Round 1 (17%)
- Debt Financing 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Passpack
|
Users can make and store passwords in a single, organized list, then access them from anywhere leaving no traces behind on the computer. Secure collaboration features allow users to make, send, share or provision passwords to colleagues, clients and partners -- a secure alternative to spreadsheets in the workplace. Managed via a central onlinerepository.Passpack is a free, professional tool. Optional premium upgrades are available for the micro-small business sector. | $950K / Debt Financing / Jun 30, 2018 | |
GreenBone Ortho
|
GreenBone develops a wood-derived bone implants technology to generate biomimetic – reabsorbable– load bearing implant suitable to address non-union fractures. The idea was conceived and developed by a research group of ISTEC-CNR of Faenza comprised of Andrea Ruffini, Simone Sprio and Anna Tampieri. | $3.3M / Sep 23, 2015 | |
CellPly
|
Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization of cancer immunotherapies, cell therapies and cell-based biotherapeutics. The company aims to support the development of novel cancer immunotherapies by accelerating R&D, automating the quality control and advancing theability to monitor the clinical response to these treatments.Through the use of proprietary microfluidic technologies with Co-Culture Array technology, highly-automated analytical instruments and AI-powered image and data analytics, Cellply products define the function of the immune system one cell at a time, combining functional data with other multiplex data and providing unprecedented single-cell analytical solutions. | $2.2M / Seed / Mar 20, 2014 | |
Angiodroid
|
Angiodroid srl, a medical technology company, focuses on hemodynamics, vascular surgery, and interventional radiology. It offers an automatic injection system for carbon dioxide angiography. Its products include carbon dioxide injector that is used as a contrast medium for pheriperal interventional angiography; and a single use kit, which iscomposed of French catheters and a custom connection line. The company is based in San Lazzaro di Savena, Italy. | $2.1M / Seed / Oct 22, 2013 | |
|
Passpack
|
Users can make and store passwords in a single, organized list, then access them from anywhere leaving no traces behind on the computer. Secure collaboration features allow users to make, send, share or provision passwords to colleagues, clients and partners -- a secure alternative to spreadsheets in the workplace. Managed via a central onlinerepository.Passpack is a free, professional tool. Optional premium upgrades are available for the micro-small business sector. | $465K / Angel / May 16, 2008 | |
Intrauma
|
Intrauma was founded in 2006 and is based in Rivoli, near Turin, in Piedmont. The company designs and manufactures the O’nil range of locking plates, which has been in clinical use since 1998. Intrauma is committed to on-going research and development of both materials and manufacturing processes, in collaboration with experienced trauma surgeons,to provide the highest quality implants and to simplify today’s approach to Traumatology. Intrauma is also dedicated to building and maintaining strong customer relationships, believing that this is the foundation of a successful business.Intrauma TODAYToday, Intrauma is the second largest supplier of trauma devices in Italy, and is rapidly expanding its international sales and marketing operations across the world.This also gives the company the opportunity to work with surgeons across the globe, developing more unique products and continuing to improve traumatology techniques for the benefit of both patient and surgeon. | $2.2M / Series A / Jan 01, 2008 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does INGENIUM Emilia Romagna invest in?
INGENIUM Emilia Romagna invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Angel stage. Most of the 6 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is INGENIUM Emilia Romagna's check size?
INGENIUM Emilia Romagna typically joins rounds of $2.1M–$2.2M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds INGENIUM Emilia Romagna participates in.
When did INGENIUM Emilia Romagna last invest?
The most recent investment recorded for INGENIUM Emilia Romagna closed in Jun 2018. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
